References of "Wagman, RB"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailTen years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial.
Bone, H.G.; Brandi, M.L.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 135-136

Detailed reference viewed: 163 (1 ULg)
Full Text
Peer Reviewed
See detailrelationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment
Ferrari, S.; ADAMI, S.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 49-50

Detailed reference viewed: 45 (2 ULg)
Full Text
Peer Reviewed
See detailA randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates
Miller, P.; Pannacciulli, N.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(SUPPLEMENT1), 42

Detailed reference viewed: 64 (2 ULg)
Full Text
Peer Reviewed
See detailThe effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
PAPAPOULOS, S.; LIPPUNER, K.; ROUX, C. et al

in Osteoporosis International (2015), 26(12), 2773-2783

Summary: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with ... [more ▼]

Summary: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with persistent reduction of bone turnover, continued increases in bone mineral density, low fracture incidence, and a favorable benefit/risk profile. Introduction: This study aims to report the results through year 5 of the FREEDOM Extension study, representing up to 8 years of continued denosumab treatment in postmenopausal women with osteoporosis. Methods : Women who completed the 3-year FREEDOM study were eligible to enter the 7-year open-label FREEDOM Extension in which all participants are scheduled to receive denosumab, since placebo assignment was discontinued for ethical reasons. A total of 4550 women enrolled in the Extension (2343 long-term; 2207 cross-over). In this analysis, women in the long-term and cross-over groups received denosumab for up to 8 and 5 years, respectively. Results Throughout the Extension, sustained reduction of bone turnover markers (BTMs) was observed in both groups. In the long-term group, mean bone mineral density (BMD) continued to increase significantly at each time point measured, for cumulative 8-year gains of 18.4 and 8.3 % at the lumbar spine and total hip, respectively. In the cross-over group, mean BMD increased significantly from the Extension baseline for 5-year cumulative gains of 13.1 and 6.2 % at the lumbar spine and total hip, respectively. The yearly incidence of new vertebral and nonvertebral fractures remained low in both groups. The incidence of adverse and serious adverse events did not increase over time. Through Extension year 5, eight events of osteonecrosis of the jaw and two events of atypical femoral fracture were confirmed. [less ▲]

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailA randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate.
MILLER, P.D.; PANNACCIULLI, N.; BROWN, J.P. et al

in Arthritis and Rheumatology (2015), 67(S10), 1181-1182

Detailed reference viewed: 51 (0 ULg)
Full Text
Peer Reviewed
See detailCan we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials.
BROWN, J.P.; DAKIN, P.; HADJI, P. et al

in Arthritis and Rheumatology (2015), 67(S10), 515-517

Detailed reference viewed: 23 (3 ULg)
Full Text
Peer Reviewed
See detailRelationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment
FERRARI, S.; LIBANATI, C.; LIN, CJF. et al

in Arthritis and Rheumatology (2015), 67(s10), 487-489

Detailed reference viewed: 25 (3 ULg)
Full Text
Peer Reviewed
See detailFurther reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
FERRARI, S.; ADACHI, J.D.; LUPPUNER, K. et al

in Osteoporosis International (2015), 26

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in ... [more ▼]

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in years 4–7 versus years 1–3. This is the first demonstration of a further benefit on fracture outcomes with long-term therapy for osteoporosis. Introduction This study aimed to evaluate whether denosumab treatment continued beyond 3 years is associated with a further reduction in nonvertebral fracture rates. Methods Participants who completed the 3-year placebocontrolled Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) study were invited to participate in an open-label extension. The present analysis includes 4,074 postmenopausal women with osteoporosis (n=2,343 long-term; n=1,731 cross-over) who enrolled in the extension, missed ≤1 dose during their first 3 years of denosumab treatment, and continued into the fourth year of treatment. Comparison of nonvertebral fracture rates during years 1–3 of denosumab with that of the fourth year and with the rate during years 4–7 was evaluated. Results For the combined group, the nonvertebral fracture rate per 100 participant-years was 2.15 for the first 3 years of denosumab treatment (referent) and 1.36 in the fourth year (rate ratio [RR]=0.64; 95 % confidence interval (CI)=0.48 to 0.85, p=0.003). Comparable findings were observed in the groups separately and when nonvertebral fracture rates during years 1–3 were compared to years 4–7 in the longterm group (RR=0.79; 95 % CI=0.62 to 1.00, p=0.046). Fracture rate reductions in year 4 were most prominent in subjects with persisting low hip bone mineral density (BMD). Conclusions Denosumab treatment beyond 3 years was associated with a further reduction in nonvertebral fracture rate that persisted through 7 years of continuous denosumab administration. The degree to which denosumab further reduces nonvertebral fracture risk appears influenced by the hip bone density achieved with initial therapy [less ▲]

Detailed reference viewed: 28 (6 ULg)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Osteoporosis International (2015), 26(S1), 149-150

Detailed reference viewed: 56 (4 ULg)
Full Text
Peer Reviewed
See detailDenosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension
Papapoulos, S; Roux, C; Bone, HG et al

in Osteoporosis International (2015), 26(S1), 37-39

Detailed reference viewed: 189 (3 ULg)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Arthritis and Rheumatism (2014), 66(11), 986-987

Detailed reference viewed: 53 (4 ULg)
Full Text
Peer Reviewed
See detailEight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension
Papapoulos, S; Lippuner, K; Roux, C et al

in Osteoporosis International (2014), 25(2), 46-47

Detailed reference viewed: 350 (2 ULg)
Full Text
Peer Reviewed
See detailFurther reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension
Ferrari, S; Adachi, JD; Lippuner, K et al

in Osteoporosis International (2014), 25(2), 56

Detailed reference viewed: 61 (3 ULg)
Full Text
Peer Reviewed
See detailDenosumab treatment of postmenopausal women with osteoporosis for 6 years : results from the first 3 years of the freedom extension
Papapoulos, S; Brown, JP; Chapurlat, R et al

in Osteoporosis International (2012, March), 23(S2), 76

Detailed reference viewed: 97 (2 ULg)
Full Text
Peer Reviewed
See detailRelationship between changes in bone mineral density and incidence of fracture with 6 years of Denosumab treatment
Bolognese, MA; Miller, PD; Reginster, Jean-Yves ULg et al

in Arthritis and Rheumatism (2012), 64(S10), 847

Detailed reference viewed: 28 (1 ULg)
Full Text
Peer Reviewed
See detailTreatment of postmenopausal women with osteoporosis for six years with denosumab : three-year results from the freedom extension
Chapurlat, R; Papapoulos, S; Brown, JP et al

in Annals of the Rheumatic Diseases (2012), 71(3), 588

Detailed reference viewed: 40 (1 ULg)
Full Text
Peer Reviewed
See detailFracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
Delmas, P. D.; Licata, A. A.; Reginster, Jean-Yves ULg et al

in BONE (2006), 39(2), 237-243

Introduction: Teriparatide is a bone formation agent that increases bone turnover and mass, resulting in an increase in bone strength and a decrease in fracture risk. Methods: The primary purpose of this ... [more ▼]

Introduction: Teriparatide is a bone formation agent that increases bone turnover and mass, resulting in an increase in bone strength and a decrease in fracture risk. Methods: The primary purpose of this analysis was to evaluate the association between pretreatment bone turnover marker (BTM) concentrations and the absolute and relative fracture risks after adjusting for baseline femoral neck BMD, number of prevalent vertebral fractures, and age. Because femoral neck BMD is commonly attained in the assessment of patients at risk for osteoporosis, we examined the ability of a multivariate assessment including pretreatment BTM concentration and femoral neck BMD to predict future fracture risk after adjusting for the number of prevalent vertebral fractures. We examined data from the Fracture Prevention Trial, a study designed to determine the effect of teriparatide 20 mcg/day and teriparatide 40 mcg/day on vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis. BTM were analyzed in two subsets of women within the Fracture Prevention Trial, and included serum bone-specific alkaline phosphatase (BSAP), serum carboxyterminal extension peptide of procollagen type I (PICP), serum amino-terminal extension peptide of procollagen type I (PINP), urinary free deoxypyridinoline (DPD), and urinary N-terminal telopeptide (NTX). Results: Teriparatide significantly reduced the risk of fracture [four BTM subset (n = 520), placebo = 14.3%, teriparatide = 5.8%, P < 0.05; PINP subset (n = 771), placebo = 17.7%, teriparatide = 5.5%, P < 0.05]. Subjects with the highest pretreatment BTM concentrations had the greatest fracture risk. Teriparatide-mediated absolute risk reduction was greatest for women with high pretreatment bone turnover; however, the relative fracture risk reduction was independent of pretreatment bone turnover. After adjusting for pretreatment BTM and number of prevalent vertebral fractures, baseline femoral neck BMD was not a significant predictor of fracture risk. Conclusion: Teriparatide-mediated relative fracture risk reduction was independent of pretreatment bone turnover, demonstrating that this therapy offers clinical benefit to patients across a range of disease severity. (c) 2006 Elsevier Inc. All rights reserved. [less ▲]

Detailed reference viewed: 26 (2 ULg)